Jaguar Health, Inc. (NASDAQ:JAGX)

COMMUNIQUÉ DE PRESSE

publié le 05/08/2024 à 16:18, il y a 1 année 7 mois

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningf
Jaguar Health, Inc. issued a letter to shareholders regarding the upcoming webcast to review second-quarter earnings and clinical data from the recent phase 3 OnTarget trial of crofelemer for breast and lung cancer patients

Crofelemer Webcast Jaguar Health Breast Cancer Lung Cancer
BRÈVE

publiée le 02/08/2024 à 16:05, il y a 1 année 7 mois

Elaine Elisabetsky, PhD, to Discuss Plant-Based Schizophrenia Treatments

Jaguar Health Magdalena Biosciences Schizophrenia Plant-based Medicine Ethnopharmacology
BRÈVE

publiée le 02/08/2024 à 16:05, il y a 1 année 7 mois

Elaine Elisabetsky, PhD, discutera des traitements contre la schizophrénie à base de plantes

Magdalena Biosciences Schizophrénie Santé Jaguar Médecine À Base De Plantes Ethnopharmacologie
COMMUNIQUÉ DE PRESSE

publié le 02/08/2024 à 16:00, il y a 1 année 7 mois

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky conducts research on plant-based medicines for mental health conditions. Jaguar out-licenses botanical drug for schizophrenia treatment to Magdalena Biosciences

Jaguar Health Magdalena Biosciences Schizophrenia Dr. Elisabetsky Plant-based Medicines
BRÈVE

publiée le 26/06/2024 à 14:35, il y a 1 année 8 mois

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Crofelemer Jaguar Health Nasdaq Compliance OnTarget Trial Cancer Supportive Care
BRÈVE

publiée le 26/06/2024 à 14:35, il y a 1 année 8 mois

Jaguar Health retrouve sa conformité avec l'exigence de prix acheteur du Nasdaq

Crofelemer Santé Jaguar Conformité Au Nasdaq Essai OnTarget Soins De Soutien Contre Le Cancer
COMMUNIQUÉ DE PRESSE

publié le 26/06/2024 à 14:30, il y a 1 année 8 mois

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities remain listed and traded on Nasdaq as Jaguar announces regaining compliance with Nasdaq's bid price requirement. Updates on cancer supportive care drug crofelemer OnTarget trial results expected by July 23, 2024

Crofelemer Nasdaq Jaguar Health OnTarget Trial JAGX
BRÈVE

publiée le 21/06/2024 à 22:20, il y a 1 année 9 mois

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Crofelemer Podcast Jaguar Health OnTarget Trial World Rainforest Day
BRÈVE

publiée le 21/06/2024 à 22:20, il y a 1 année 9 mois

Jaguar Health annonce l’approbation de toutes les propositions lors de l’assemblée annuelle des actionnaires de juin 2024

Crofelemer Podcast Santé Jaguar Essai OnTarget Journée Mondiale De La Forêt Tropicale
COMMUNIQUÉ DE PRESSE

publié le 21/06/2024 à 22:15, il y a 1 année 9 mois

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar Health, Inc. to report pivotal phase 3 OnTarget trial results for cancer supportive care drug crofelemer by July 23, 2024. Investor webcast and podcast interview updates included

Crofelemer Investor Webcast Jaguar Health OnTarget Trial Cancer Supportive Care

Publié le 25/03/2026 à 18:53, il y a 1 heure 31 minutes

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Publié le 25/03/2026 à 18:53, il y a 1 heure 31 minutes

LNA SANTE : 2025 Annual Results
Publié le 25/03/2026 à 18:31, il y a 1 heure 53 minutes

Strong investment performance and active roll-out of our strategy
Publié le 25/03/2026 à 18:31, il y a 1 heure 53 minutes

Performance soutenue des Investissements et déploiement actif de la stratégie
Publié le 25/03/2026 à 18:06, il y a 2 heures 18 minutes

LNA SANTE : Résultats Annuels 2025

Voir tout LES ECHOS COMFI WIRE

Publié le 25/03/2026 à 19:15, il y a 1 heure 10 minutes

Gemina Laboratories Ltd. Announces Delisting from the CSE
Publié le 25/03/2026 à 13:30, il y a 6 heures 55 minutes

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Publié le 25/03/2026 à 13:30, il y a 6 heures 55 minutes

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Publié le 25/03/2026 à 13:30, il y a 6 heures 55 minutes

Strategic Metals Closes Project Sale
Publié le 25/03/2026 à 13:25, il y a 7 heures

Predictiv AI Expands Active Deployment of CloudRep.ai Across Healthcare, Retail, Real Estate, Travel and Global Markets

Voir tout ACCESSWIRE

Publié le 25/03/2026 à 20:00, il y a 24 minutes

Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Publié le 25/03/2026 à 19:41, il y a 43 minutes

EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Publié le 25/03/2026 à 19:30, il y a 54 minutes

AIXTRON to expand global footprint with new plant in Malaysia
Publié le 25/03/2026 à 19:26, il y a 58 minutes

EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia
Publié le 25/03/2026 à 18:40, il y a 1 heure 44 minutes

TULKUBASH AND KYZYLTASH MINING ASSETS: DECLARATION FROM A GROUP OF INVESTORS

Voir tout EQS

News